Stockscreener 앱 받기
61.23
3.17%
1.88
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent - MSN
Does Ionis Pharmaceuticals Inc. stock have upside surprise potentialQuarterly Growth Report & Expert-Curated Trade Recommendations - خودرو بانک
Ionis Pharma director Loscalzo sells $962k in shares By Investing.com - Investing.com Australia
What are analysts’ price targets for Ionis Pharmaceuticals Inc.2025 Key Lessons & Precise Buy Zone Tips - خودرو بانک
Ionis Pharma EVP Baroldi sells $1.95m in shares By Investing.com - Investing.com Australia
Ionis Pharmaceuticals director Wender sells $1.6m in shares By Investing.com - Investing.com South Africa
Is Ionis Pharmaceuticals Inc. a potential multi baggerJuly 2025 Price Swings & Long-Term Safe Return Strategies - خودرو بانک
What is the earnings history of Ionis Pharmaceuticals Inc.Quarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
How sentiment analysis helps forecast Ionis Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Ionis Pharmaceuticals Stock (IONS) Opinions on Olezarsen Trial Results and FDA Approval - Quiver Quantitative
Ionis pharma EVP O’Neil sells $5.39 million in IONS stock - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares By Investing.com - Investing.com Nigeria
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Market reaction to Ionis Pharmaceuticals Inc.’s recent newsTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 38% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Stock Rankings & Expert Curated Trade Ideas - Newser
Assessing Insider Selling at Ionis Pharmaceuticals: Implications for Investor Confidence and Stock Valuation - AInvest
Ionis Pharmaceuticals Insider Sold Shares Worth $2,301,264, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals Insider Sold Shares Worth $5,396,843, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals Insider Sold Shares Worth $1,946,220, According to a Recent SEC Filing - MarketScreener
Insider Selling at Ionis Pharmaceuticals: A Signal or a Symptom? - AInvest
Real time breakdown of Ionis Pharmaceuticals Inc. stock performanceJuly 2025 Momentum & Low Risk High Reward Trade Ideas - Newser
Ionis Pharma director Klein sells $1.68 million in shares - Investing.com India
Ionis Pharma EVP Baroldi sells $1.95m in shares - Investing.com India
Ionis Pharmaceuticals director sells $1.6m in IONS stock By Investing.com - Investing.com Canada
Ionis pharma EVP Devers sells $192,942 in IONS stock By Investing.com - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares - Investing.com
SEC Filings Archive 2025-09-04Historical 10-K, 10-Q, 8-K Forms - Stock Titan
Ionis Pharma director Loscalzo sells $962k in shares - Investing.com
Ionis Pharmaceuticals director Klein sells $1.68 million in shares - Investing.com India
Ionis pharma EVP Devers sells $192,942 in IONS stock - Investing.com India
Insider Sell: Brett Monia Sells 203,814 Shares of Ionis Pharmace - GuruFocus
Ionis Pharmaceuticals director Wender sells $1.6m in shares - Investing.com
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock - Investing.com India
Ionis Pharma EVP Geary sells $503,671 in IONS stock - Investing.com
Ionis Pharmaceuticals director sells $1.6m in IONS stock - Investing.com
How to use a screener to detect Ionis Pharmaceuticals Inc. breakoutsQuarterly Trade Review & Risk Controlled Daily Plans - Newser
Ionis Pharmaceuticals director Klein sells $1.68 million in shares By Investing.com - Investing.com UK
Ionis Pharma director Klein sells $1.68 million in shares By Investing.com - Investing.com UK
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock By Investing.com - Investing.com UK
Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen - MSN
Ionis Falls 1.88% with 63% Volume Drop Ranking 457th as BMO Upgrades to 'Outperform' on Breakthrough Drug Outlook - AInvest
Ionis Pharmaceuticals’ Strategic Position in the Biotech Sector: Growth Potential in Therapeutic Innovation and Market Leadership - AInvest
What drives Ionis Pharmaceuticals Inc.’s stock price2025 Volume Leaders & Proven Capital Preservation Methods - خودرو بانک
Is Ionis Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & AI Based Trade Execution Alerts - خودرو بانک
RBC Capital Adjusts Price Target on Ionis Pharmaceuticals to $80 From $70, Maintains Outperform Rating - MarketScreener
Is Ionis Pharmaceuticals Inc. stock entering bullish territoryMarket Activity Report & AI Forecast for Swing Trade Picks - Newser
When is the best time to exit Ionis Pharmaceuticals Inc.July 2025 Momentum & Fast Entry High Yield Stock Tips - Newser
RNA Therapeutics Market Size, Top Share | Industry Report, 2034 - Straits Research
What’s next for Ionis Pharmaceuticals Inc. stock priceDollar Strength & Community Driven Trade Alerts - Newser
Ionis Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - Newser
Building trade automation scripts for Ionis Pharmaceuticals Inc.Market Volume Report & Real-Time Chart Breakout Alerts - Newser
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Street Watch: Is Ionis Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Catalysts & Consistent Profit Trade Alerts - خودرو بانک
Ionis Pharmaceuticals Executives Buy Shares Amid Recent Market Volatility. - AInvest
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical - openPR.com
Ionis Pharmaceuticals stock surges following BMO Capital upgrade - AInvest
Ionis Pharmaceuticals Shares Rise After BMO Capital Upgrade - MarketScreener
Key resistance and support levels for Ionis Pharmaceuticals Inc.M&A Rumor & Daily Stock Trend Reports - Newser
1.40%
자본화:
|
볼륨(24시간):